Dutasteride

證據等級: L5

預測適應症: 10 個

Dutasteride: From Androgen-Dependent Conditions to Ambras Type Hypertrichosis Universalis Congenita

One-Sentence Summary

Dutasteride is a 5α-reductase inhibitor best known for use in androgen-dependent conditions (e.g., benign prostatic hyperplasia, androgenetic alopecia); its formal original-indication and MOA records are flagged as a data gap in this evidence pack (DG001, DG002). The TxGNN model’s top prediction is Ambras Type Hypertrichosis Universalis Congenita, but this is supported by 0 clinical trials and 0 publications, and the mechanism runs in the opposite pharmacological direction from what the disease would require.

Quick Overview

Item	Content
Original Indication	Not documented in this evidence pack (no TFDA license records; `original_indications` is empty). Rationale text references androgen-dependent conditions (e.g., BPH/AGA) as the drug’s known use area — see DG002.
Predicted New Indication	Ambras Type Hypertrichosis Universalis Congenita
TxGNN Prediction Score	99.998%
Evidence Level	L5 (model prediction only, no clinical trials or literature)
US Market Status	✗ Not Marketed
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed, sourced mechanism-of-action data is not available for this drug (DG002, High severity — remediation: query DrugBank API). Based on information embedded in the model’s own repurposing rationale, dutasteride is a 5α-reductase inhibitor that lowers dihydrotestosterone (DHT); pharmacologically this direction is “reduce androgen-driven hair growth,” which is why it is used for conditions like benign prostatic hyperplasia and androgenetic alopecia.

Ambras type hypertrichosis universalis congenita is a congenital, autosomal-dominant disorder (linked to 8q chromosomal rearrangement) driven by structural follicular activation that is not androgen-dependent. The evidence pack’s own rationale explicitly flags this mismatch: dutasteride’s DHT-lowering mechanism points toward reducing hair growth, while this condition would require the opposite. The rationale attributes the model’s high score to graph-embedding proximity (hair-related node clustering in the knowledge graph) rather than a genuine mechanistic relationship.

Given this, the prediction should be treated as a signal for further investigation of the TxGNN graph topology rather than a clinically plausible repurposing hypothesis at this time.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

US Market Information

Dutasteride is not marketed in this jurisdiction (market_status: 未上市 / Not Marketed; total_licenses: 0). No license records are available to summarize.

Safety Considerations

Please refer to the package insert for safety information. (Key warnings, contraindications, and DDI data are all marked as data gaps in this evidence pack — DG001, Blocking severity, blocks the S1 safety pre-screen; remediation requires downloading and parsing the TFDA package insert.)

Conclusion and Next Steps

Decision: Hold

Rationale: The top-ranked prediction has no clinical trial or literature support (L5, decision stage S0), and the drug’s own known mechanism (DHT reduction) runs counter to what Ambras type hypertrichosis would require — the rationale itself attributes the score to likely graph-embedding noise rather than a real signal.

To proceed, the following is needed:

TFDA package insert (warnings/contraindications) — currently blocking (DG001)
Verified mechanism of action and original indication data via DrugBank API (DG002)
Investigation of why the TxGNN graph clusters dutasteride with structural/congenital hair disorders, to rule out embedding artifacts
Note: rank 8, diffuse alopecia areata, was separately scored L4/S1 (“Research Question”) based on one retrieved review — but that review discusses androgenetic alopecia, not alopecia areata, so the disease-node mapping should be manually verified before treating it as a stronger candidate than rank 1
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.